Centessa Pharma enters into $250M ATM equity offering facility with Leerink Partners

Centessa Pharmaceuticals plc

Up to $250M of American Depositary Shares may be sold through Leerink as sales agent.
Commission of 3.0% on gross proceeds; Leerink also receives up to $150K legal expense reimbursement.
No minimum offering amount; net proceeds expected for working capital, capex, and general corporate purposes.
Amends and restates prior sales agreement dated January 27, 2023, with Leerink.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.